Global markets remained mixed after a potential COVID-19 vaccine trial got halted - Wednesday Review, October 14

Global markets remained mixed after a potential COVID-19 vaccine trial got halted - Wednesday Review, October 14

Mixed performance from the markets

The US

The effect created by the latest Apple event lost some steam, benchmarks closing in the red. USA30 fell 0.34%, while USA500 lost 0.45%. TECH100 was down 0.57%.

Oil was up 2.1% to $41.04 per barrel. Brent Oil gained 2% to $43.32.

Gold rose 0.7% and settled at $1,907.30 per ounce.

Asia and Australia

The markets were mixed. Most were driven by the temporary pause in the human trials of a potential COVID-19 vaccine, while others focused on the earnings reports from some of America's largest banks.

Japan225 went up 0.07%.

HongKong45 gained 0.04%.

Down under, Australia200 lost 0.08%.

Europe

Germany30 went up 0.1%. UK100 gained 0.4%, while France40 fell 0.1% ahead of the annual meetings of the International Monetary Fund, the World Bank Group, and the European Central Bank.

EUR/USD lost 0.1% to 1.1736.

Sources: reuters.com, investing.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.